HLA
CORT icon

Hamilton Lane Advisors’s Corcept Therapeutics CORT Stock Holding History

Hamilton Lane Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-167,630
Closed -$1.22M – 61
2016
Q4 		$1.22M Buy
+167,630
New +$1.31M 0.8% 33
2015
Q4 		– Sell
-21,419
Closed -$81K – 51
2015
Q3 		$81K Buy
+21,419
New +$109K 0.04% 47

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Hamilton Lane Advisors's CORT Position: Q1 2017 in Review

Hamilton Lane Advisors sold out of Corcept Therapeutics (CORT) in Q1 2017, closing a stake of 167,630 shares — an estimated $1.22M sold.

Hamilton Lane Advisors first reported a position in CORT in Q3 2015 and held it in 2 quarters. The position peaked at $1.22M in Q4 2016. 135 funds tracked by Wall St. Rank hold CORT as of Q1 2017.

  • Hamilton Lane Advisors reported no remaining Corcept Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Hamilton Lane Advisors sold 167,630 Corcept Therapeutics shares in Q1 2017, an estimated $1.22M.
  • Hamilton Lane Advisors first reported a position in Corcept Therapeutics in Q3 2015 and held it in 2 quarters.
  • Hamilton Lane Advisors's Corcept Therapeutics position peaked at $1.22M in Q4 2016.
  • 135 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2017.

Based on Hamilton Lane Advisors's 13F filing for Q1 2017, filed 24 Apr 2017.